Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.25 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (pancreatic islet cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: fasiglifam, setogepram, ly2881835 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 5 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1696
Sealed predictions
- FFAR1 in dopamine neurons, braak-0.69 (p 0.041) → -0.50 (p 0.166)receipt 1701
Swarm cases
receipt 1701: FFAR1 in dopamine neurons, braak
- power
- full sample -0.66 (p 0.0028, n 18), 95% CI -0.86 to -0.28. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.62 (p 0.0060, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.60 (p 0.0089, n 18). not the mix.
- skeptic
- leave-one-out range -0.75 to -0.62, sign flips 0; without severely affected donors -0.66 (p 0.0028, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.72 (p 7.4e-4, n 18) vs -0.66 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FFAR1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FFAR1 · oligodendrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts